Literature DB >> 678104

Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.

E L Felix, J M Jessup, M H Cohen.   

Abstract

Since the introduction of BCG intralesional immunotherapy for melanoma, severe complications, including death, have been reported after treatment in hypersensitized individuals. This is a case report of BCG dissemination with ulceration, skin necrosis, lymphadenitis, and abscess formation following the first intralesional injection of a minimal dose of BCG in a PPD-negative patient. The case demonstrates that severe complications can occur in patients who are not hypersensitized, anergic, or debilitated or who have been treated multiple times. This patient's complication further suggests that migration of BCG after intralesional therapy may play a role in the regression of uninjected nodules seen in some patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 678104     DOI: 10.1001/archsurg.1978.01370190115025

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

Review 1.  Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.

Authors:  Mark B Faries
Journal:  Crit Rev Oncog       Date:  2016

2.  A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma.

Authors:  Eiji Kiyohara; Atsushi Tanemura; Kazuma Sakura; Toshihiro Nakajima; Akira Myoui; Naoya Yamazaki; Yoshio Kiyohara; Ichiro Katayama; Manabu Fujimoto; Yasufumi Kaneda
Journal:  Cancer Immunol Immunother       Date:  2022-01-05       Impact factor: 6.630

Review 3.  Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma.

Authors:  Dejan Vidovic; Carman Giacomantonio
Journal:  Cancers (Basel)       Date:  2020-05-22       Impact factor: 6.639

4.  Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.

Authors:  Paul Toomey; Krithika Kodumudi; Amy Weber; Lisa Kuhn; Ellen Moore; Amod A Sarnaik; Shari Pilon-Thomas
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.